-

Metagenomi Announces Participation in September Investor and Industry Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR gene editing tools, today announced its participation in the following investor and industry conferences:

Citi’s 17th Annual BioPharma Conference
Company Panel titled “Private Co-Panel: Genetic Medicine” on September 7, 4:20 - 5:05 p.m. EDT
1×1 meetings with institutional investors
Participants: Brian C. Thomas, Ph.D., CEO and founder, and Simon Harnest, CIO, SVP Strategy

Wells Fargo Healthcare Conference
Corporate presentation with Q&A on September 9, 10:25 - 10:55 a.m. EDT
1×1 meetings with institutional investors
Participants: Brian C. Thomas, Ph.D., CEO and founder, and Simon Harnest, CIO, SVP Strategy

Baird’s 2022 Global Healthcare Conference
Corporate presentation with Q&A on September 13, 9:40 - 10:10 a.m. EDT
Participant: Simon Harnest, CIO, SVP Strategy

GENedge’s GEN The State of Biotech Virtual Summit
Pre-recorded presentation, September 21-22
Participant: Brian C. Thomas, Ph.D., CEO and founder

Jefferies Cell and Genetic Medicine Summit
Corporate presentation with Q&A on September 30
1×1 meetings with institutional investors
Participant: Simon Harnest, CIO, SVP Strategy

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.

Contacts

Investor Contact:
Simon Harnest, CIO, SVP Strategy
simon@metagenomi.co
+1 (917) 403-1051

Media Contact:
Ashlye Hodge
ashlye@metagenomi.co
+1 (510) 734-4409

Follow us on Twitter and connect with us on LinkedIn.

Industry:

Metagenomi

Details
Headquarters: Emeryville, California
CEO: Brian Thomas
Employees: 137
Organization: PRI
Release Versions
English

Contacts

Investor Contact:
Simon Harnest, CIO, SVP Strategy
simon@metagenomi.co
+1 (917) 403-1051

Media Contact:
Ashlye Hodge
ashlye@metagenomi.co
+1 (510) 734-4409

Follow us on Twitter and connect with us on LinkedIn.

More News From Metagenomi

Metagenomi Appoints Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, today announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer. “I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and fou...

Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting. The presentations demonstrate enhanced efficiency of Metagenomi’s proprietary type V and type II nucleases, first-in-class CAST systems for large, targeted DNA integration capabilities, and novel base editing sy...

Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, announced it will present new data during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting in Los Angeles (May 16-20). “As we advance the field of genetic medicines, we need to develop novel gene editing systems that allow us to address and correct the underlying disease-causing genes with precision and efficiency....
Back to Newsroom